Qiagen Acquires Diagnostic Shop Genaco for $22M in Cash | GenomeWeb
NEW YORK (GenomeWeb News) — Qiagen last week acquired Genaco Biomedical Products for $22 million in cash, the company said today.
 
Qiagen purchased 100 percent of the company’s outstanding stock, and will pay out as much as $18 million in milestone payments from anticipated grants.  
 
Genaco is an early-stage company that uses a proprietary PCR-based multiplexing technology, called TEM-PCR, in its Templex molecular diagnostics, Qiagen said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.